Search
After receiving a CRL for its RP1 oncolytic immunotherapy yesterday, the CEO of Replimune walks us through the program's timeline and history, and what this might mean for its future
CEO Sushil Patel walks us through the decisions behind the design of the IGNYTE phase 1/2 study and the ongoing IGNYTE-3 study, he gives...
Jul 23
Replimune's CEO discusses last week's PD-1 refractory melanoma data and the company's plans to file for accelerated approval
Sushil Patel describes Replimune's ASCO and follow-on data from last week in the context of PD-1 response rates and competitor data from...
Jun 10, 2024
.png){kind=logo}
